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Several groups have investigated the role ofT cells in 
the pathogenesis of psoriasis by determination of 
T -cell receptor (TCR) B-chain variable (V) regiQn 
usage, both in chronic plaque (psoriasis vulgaris) and 
guttate forms, with various results . Because there are 
no data on TCR eX:pression in early psoriasis vulgaris, 
when specific cellular immune events may be ex-
pected to be most pronounced, we have analyzed 
early lesions (less than 3 wk old) of ten patients, with 
highly reproducible results . We have developed a 
highly controlled anchored polymerase chain reac-
tion (PCR) method in which TCR J3 chain species are 
all amplified with the same ·primer pair and products 
are quantified by dot blot hybridization with BV 
family-specific oligonucleotide probes. Overexpres-
sion of certain TCR BV genes was observed in the 
majority oflesional biopsies, but in samples in which 
T he pathogenesis of psoriasis involves both genetic p redisposition. , including t.he influence of genes of the H LA com.plex (Elder et a!, 1994) , and T -cell depen-dent mechanisms. Evidence for the latter includes: infiltratio n oflesio ns with activ ated T cells (Bos et al, 
1983; Baker et. al, 198 4); the therape utic effic acy of cyclosporin A 
(Van Joost et. al, 1988), FK 506 Qegasothy et al, 1992) , anti-CD4 
monoclonal antibody (Nicolas et al, 1991), and a lymphocyte-
selective toxin (Gottlieb et al, 1995) ; raised serum levels o f soluble 
interle ukin-2 recep tor protein during active phases o f disease (Kapp 
eta/, 1988); the presence o f prolifera ting T cells in association with 
dendritic cells in lesions (Morganroth et al, 1991) ; the ability of 
lesional epidenn al cell suspen sions to drive autologous peripheral 
blood lymphocyte (PBL) proliferation (Baadsgaard et al, 1989) 
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the expanded BV family formed more than 10% of 
totallesional BV (half of the samples analyzed), BV2 
and BV6 predominated. The consistency of overex-
pression of these BV species between patients was 
much less than in previous studies of TCRBV usage 
in established chronic plaque psoriasis lesions. 
Compleme.ntarity-determining region 3 (CDR3) size 
spectratyping demonstrated evidence for selective 
clonal T cell accumulation in less than half of the 
lesional samples showing BV expansion. These re-
sults indicate that selective amplification of TCRBV 
species occurs in early psoriasis vulgaris but is not 
essential to the pathogenic process and may be more 
important in the maintenance or expansion of 
chronic lesions . Key words: lymplwcytes/clonality. J Invest 
Del"tnatol 109:5- 13, 1997 
suggesting local antigen presentation; and the dem onstration that 
lesional T - cell clo nes release growth factors that induce keratino-
cyte pro liferation (Stan ge et a/, 1993). T hese findings have led to 
the sugges tio n that psoriasis m ay be an a utoimmune disease, with 
T - cell activation being initiated in the guttate fo rm o f the disease by 
locally released strep tococcal superantigens (Valdimarsson et a/, 
1995) . 
T h e response o f T cells to antigen commonly depends on the 
interaction of clono typic a {3 T - cell receptor (TCR) species wi th 
p eptides presen ted in major histocompatibility complex molecules 
on antigen-presenting cells (Marrack and Kappler, 1987) . As an 
oligoclonal T - cell response m ay il1dicate reaction to antigen and 
responses to superantigen are characterized by activati.on ofT cells 
expressing distinct TCR {3-chain variable (V ) region (BV) sp ecies 
(Kotzin et a/, 1993 ), it is logical that important il1fo rmation abo u t 
the pathogenesis of psoriasis may be gained by studyin g TCR gene 
expression in lesions. Several such studies have been rep orted 
recently. Lewis et a/ (1 993) w ere the fust to rep ort remarkable 
skewing o f TCR gene expression in the lesions of guttate and 
chr onic plaque psorias is, by using a .limited pan el o f BV m onoclonal 
antibodies and iin~unochemical analysis o f biopsies and autologous 
PBLs. Specifically, increased numbers o f lesional T cells expressii1g 
Vf32 gene family and V{35.1 subfamily products [BV2 and BV5S1 
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Table I. Patient Details" 
Age of Time of 
Age Duration of Biopsied PAS I Last 
Patient (y) Sex Psoriasis Plaque Scorch HLA Status Treatment 
A 45 M Sy 1 wk 9.3 A2, B39, B44, Cw5, DR4, DR14 11d 
B 28 M 17 y 2wk 4.5 ND' 2 wk 
c 35 M 13 y AE' 9.9 A1, A2, B37, B44, Cw5, Cw6, DR4, DR10 6 wk 
D 32 M 6 mo 2 wk 9.9 ND 2 wk 
E 27 M 13 y 2 wk 4.8 ND 2 wk 
F 35 M 14 y 1 wk 15.4 ND 1 wk 
G 50 F 18 y 4d 6.0 Al, A2, B13, B57, Cw6, DR7 1 wk 
H 60 M 45 y 2 wk 15.3 All, A24, B39, B62, Cw3, DR15 1 wk 
I 49 M 9y 1 wk 2.4 ND 1 wk 
J 49 M 32 y AE 8.0 A2, B35, B38, Cw3, Cw4, DR13, DR15 7 wk 
" All p;1ticnts had deteriorating chronic plaque psoriasis. No samples were obtained from gutt;:ltc psoriasis lesions. 
• PASI , psoriasis area and severity index (Frcdricksson and Pettcrsson, 1978). 
r AE . adv:mcing edge; ND , not determined. 
according to recently proposed reference sequence nomenclature 
(Wmiams et al, 1995), which is hereafter used in this paper] were 
reported. Recently, Leung et al (1995) have supported these 
findings by reporting increased BV2 expression particularly in 
perilesional skin biopsies in guttate psoriasis, by using inununohis-
tochemical techniques and the •same BV2 monoclonal antibody 
used by Lewis et al (1993). Subsequent polymerase chain reaction 
(PCR) amplification of lesional eDNA with B-chain constant (C) 
region and BV2-specific primers and sequence analysis of hyper-
variable (variable-diversity-joining) regions in BV2-exFressing 
clones, revealed extensive variable-diversity-joining region diver-
sity more compatible with the efFects of superantigen (possibly 
streptococcal pyrogenic exotoxin C) than conventional antigen. 
Menssen et al (1995) have recently reported prominent overexpres-
sion ofBV2 and BV6 f."lmilies in biopsies of chronic plaque psOL;asis 
lesions, by using a PCR method incorporating a panel of BY-
specific primers based on the sequences of Choi et al (19S9). In 
contrast to the results reported in guttate psoriasis (Leung et al, 
1995), however, sequence analysis of transcripts from three patients 
revealed evidence for TCR oligoclonality and conserved junctional 
motifs between patients, compatible with the effects of conven-
tional antigen rather than superantigen. Overexpression ofBV2 and 
BV6 was also found in clinically normal skin, but sequence analysis 
of transcripts revealed variable-diversity-joining region diversity. 
Chang et al (1994) isolated CDS + T cells from3-cm 2 shave biopsies 
of psoriasis lesions and reported overexpression of BV3 and 
BV13S1 in this subpopulation in 9 of 11 patients but not in lesion a! 
CD4 + cells, by using PCR with multiple BV family-specific 
primers also based on the sequences of Choi et a/ (19S9). Finally, 
Boehncke et al (1995), using PCR and a different set of multiple BV 
family-specific primers based on the sequences of Hall and Finn 
(1992), found some restriction ofBV usage in psoriatic lesions in as 
much as some V regions expressed on PBLs were absent from the 
skin. There was, however, no increase in the expression of 
individual BV species in lesions compared with PBLs and no pattern 
of restriction between patients. 
Thus, reported patterns ofBV expression in psoriatic lesions have 
been inconsistent, a finding that may be the result of several factors 
including immunogenetic difterences between patients; differences 
in the type, age, and activity of lesions; and variations in methods 
used. In this respect, the molecular methods used in the research 
cited above aJJ relied on primer-directed PCR, in which eDNA 
amplification is carried out with a C-region 3' primer and a large 
panel ofBV family-specific 5' primers in multiple reactions. While 
primer-directed PCR bas provided useful results, it is theoretically 
possible that large panels of BY-specific primers may produce a 
biased representation of BV expression, through differences in 
amplification efficiency arising mainly from tl1e different melting 
temperatures of primer-target hybrids (Hall and Film, 1992). Thus, 
it has been suggested that primer-di.J:ected PCR may only be 
reliable when making i.J1tersample comparisons with the same BV 
pri.J11er set (Genevee eta/, 1992). On these theoretical grounds, we 
have devoted considerable effort td the development of an an-
chored PCR method that allows amplification of all TCR B-chain 
species in a sample with the same primer pair. This is likely to 
provide more quantitative relative expansion ofBV families, which 
may be measured ii1 PCR products by cloning, probii1g, and 
sequencii1g (Rosenberg et a/, 1992) or by solid-phase hybridization 
with a panel of BV -family- specific probes (Kohsaka et al, 1993). 
We have applied our highly controlled and reproducible anchored 
PCR method to the analysis of extracts of early plaque psoriasis 
lesions, because we judged that specific cellular immunologic 
events may be more readily detectable in early lesions. Tlus has 
necessitated the biopsy of small lesions, some only a few millimeters 
ii1 diameter, and precluded the analysis of separated lesional CD4 + 
and CDS + T-cell subtypes because it was anticipated that tlus 
would require larger samples. PCR products have been quantified 
by dot blot hybridization with a unique panel ofBV -family-specific 
oligonucleotide probes. Any apparent expansion of BV families in 
skin lesions compared with autologous PBL was further investi-
gated by primer-directed PCR and complementarity detennining 
region (CDR3) size spectratyping on denaturing polyacrylamide 
gels (Gorski eta/, 1994; Yurovsky eta/, 1994), to allow determi-
nation of the clonality of the expanded families. 
MATERIALS AND METHODS 
Clinical Samples After local ethics committee approval and provision of 
informed consent, peripheral venous blood and punch biopsy samples of 
skin lesions were obtained from ten patients with deteriorating chronic 
plaque psoriasis. Details of the patients, who had been oft" active topical or 
systemic treatment for at least 1 wk, are given in Table I. Pw1eb biopsies ( 4 
mm in diameter) were obtained under lignocaine local anesthesia either 
from early small skin lesions (less than 3 wk old} or in 1:\vo patients from the 
active advancing edges of established lesions traced as previously described 
(Macdonald Hull e/ a/, 1989). Immediately after excision the skin samples 
were frozen and stored under liquid nitrogen. Peripheral blood (20-40 ml) 
was collected into acid citrate/dextrose anticoagulant and diluted with an 
equal volume ofmodifted Earle's balanced salt solution (lCN Flow, Thame, 
U .K.). The suspension was centrifuged on Lymphoprep (GffiCO, Paisley, 
U .K .), and the peripheral blood mononuclear cells (PBMCs) at the interface 
were collected and washed twice with PBS. PBMCs were stored as pellets 
at -sooc w1til required for RNA extraction. PBMCs were also obtained 
from four normal volunteers (one female and three males, aged 22-39 y), to 
aUow comparison of PBMC TCR B-chain profiles between the psoriasis 
patients and normal volunteers. Human leukocyte a.ntigen typing was 
carried out by the Transplant Laboratory, Department of Surgery, Leices ter 
General Hospital, Leicester, U.K., with a combination of serologic and 
PCR-based teclmiques. 
RNA Isolation and eDNA Preparation AJJ reagents and enzymes used 
were obtained from Life Technologies (Paisley, U .K .) unless otherwise 
stated. Total RNA was isolated from PBMCs with TRizol following the 
supplier's instructions. Tlus protocol is a development of the gumudinium 
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isothiocyanatc/ phenol /chlo roform method of C homczynski and Sacchi 
{1987). Tota l RNA w"s isolated from the skin samples by fine maceration 
of biopsies on dry ice with a sterile sca lpel blade, dispersion of macerated 
skin in TR!zol with a motorized polypropylene pestle and mortar, fo llowed 
by precipitation and washing steps as for the PBMC RNA . After isolation , 
R.NA concentration was calculated from the optica l density at 260 Illll by 
capillary ul trav io let spectroscopy. Contaminating DNA was removed by 
incubation with l~ase- free DNase l (Lorne, Twyford, U.K.; 2 un.its of 
DNase per J.Lg of RNA for 1 h at 37°C) and RNA was recovered by 
phenol/chloroform extraction . This step was in trod uced in view of evi-
dence for substancial carq ' over of DNA in the initial extraction, as 
demonstrated by the presence of DNA bands on agarose gels after PCR of 
RNA extracts that had not undergone reverse transcription. No DNA 
amplifica tion was demonstrable after PCR of DNase-digested non-re-
versed-transcribed extracts (data not shown). After DNase digestion l~A 
was requantifi ed by ul traviolet spectroscopy and a small aliquot was 
exami11ed by agarose ge l electrophores is to check the integrity of ribosomal 
l~A bands. Typica lly, a 4-mm punch biopsy of a psoriasis lesion yielded 
approx.imate ly 2 f.lg ofDNA- free RNA. TCR B-chain eDNA was synrhe-
sized fi·om 50 ng (PBMC) or 200 ng (skin) tota l I~ A. 40 pmol of reverse 
transcription primer CJ3R, 5' -GCTCTACCCCAGGCCTCGGCGC-3' 
(Rosenberg ct al, 1992), which recognizes bases 365-386 conunon to both 
B-chain C region sequences, and 200 uni ts of Superscript Jl reverse 
tra nscript<tse (GlBCO , Paisley, U.K.) in a total volume of20 f.ll. eDNA was 
precipitated three times with 3 M ammonium acetate a.nd ethano l to remove 
unincorporated nucleo tides and then tailed with poi)'(A) by reaction with 
deoxyadenosine triphosp hate and terminal dem.:y nucleotidyltransferase. 
A11chored PCR For anchored PC R , one forward primer a.nd rwo reverse 
pimers were used. The forward primer 5 '-CCCGGGGATCCAAGC(T) ,. -3' 
(BHT) in~orporates recognition sequences for the restriction enzymes 
BamHl and Hiudlll and h)'bridizes to the poly(A) anchor. The rwo reverse 
primers were CJ3A (5' -CCATGGTACCTCGAGTCGACTGTGCAC-
CTCCTTCCCATTC-3') recognizing bases 141-162 and CJ31 5'-CGGCG-
GTCGACTCTGCTTCTGATGGCTCAAAC-3' complementary to bases 
39-60. Both C/3A and CJ31 contain a Sail recognition site to facilitate 
subsequent clon ing of PCR products. T he two reverse primers recognize 
equi va len t residues in both D-elwin C region sequences. T he procedure fo r 
anchored PCR is based on that of Loh et a/ (1989). Each eDNA was 
separated into four aliquots for PCR. Each reaction was ca rried out in a fina l 
volume of 50 J.Ll containing tailed eDNA, PCR bu.ffer (20 mM Tris(hy-
droxymethyl)aminomcthane hydrochloride, pH 8.4, 50 mM KCl), all four 
deoxynucleotide triphosphates (each at 250 fLM), 2.5 mM MgC12 , l fLM 
primer DHT, 1 J.LM primer CJ3A, and 2.5 units of Taq pol)'merase (GIBCO, 
Paisley, ~.K.). Samples were overlaid with rwo drops of mineral oi.l (Sigma, 
Poole, U .K.). R eactions were then denatured at 94°C for 60s, annealed at 
55°C for 60s, and extended at 72°C for 180 s for 20 cycles, followed by a 
final extension pei:iod at 72°C for 10 min. At the end of the amplification, 
a smaU aliquot of each sample and the wa ter blank were checked by 
electrophoresis i.n a 1.5% agarose gel and Tris(hydroxymetlJyl)am inometh-
ane/acetate buffer. R eplicate PCR prod ucts were pooled and precipitated 
with sodium acetate and e tl1anol before separation in 1.5% agarose. Bands 
in agarosc ge ls containing DNA migrating between 500- and 800-base-pair 
standards were excised and the DNA was recovered with Qiaex II (Qiagen, 
Dorking, U .K.) according to the manufacturer's protocol. DNA was elu ted 
in water and the concentration was determined by ultrav iolet spectroscopy. 
Putified first-round PCR products (five 20-ng ajjquots) were then used to 
set up a second round of amplification u11der the same conditions used for 
the first round PCR, with th e exception that internal 3' primer CJ31 was 
used in place of CJ3A. Afte1· amplification, an aliquot was checked by 
agarose ge l electrophores is. The replicate PC R.s for each sample were 
pooled and the mi.ncral oi l was removed. Amplified TCR eDNA was then 
separated from uninco.rporated primers and nucleotides by fractionation 
with tl1e Wizard D NA purification system (Promega, Southampton, U .K.) 
according to the maiHifiiCtlll·er's instructions, and tl1 e purified eDNA was 
again quantified by ultraviolet spectroscopy. 
TCRBV -Family-Specific Oligonucleotide Probes Specific oligonu-
cleotide probes for 24 TCRBY famil ies were rigorously designed. A 
co llection of all avai lable sequences was compiled from the GenBank/ 
EMBL database, which generated 202 acccss iou numbers (Table ll) . T hese 
sequences were used to design oligonucleotide probes that detect all 
members of each BY family bur maintain minimal in terfamily cross-
reactivity . Initially sequences were imported into DNA Inspector lie 
(Textco, West Lebanon, NH) and pairwise homology analysis was per-
formed to identify regions of identity between members of the same f:unily 
and regions of sequence with minimal similari ty to other fa milies. Candidate 
Probe sequences were then selected and by adjusting the probe lengtl1, and 
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G + C content melting temperatures (T,..) were maintained witltin rhe range 
63.5 and 69.5°C, as calculated by the formula T.., 81.5 + 
16.6(log10[Na +]) + 0.41(fraction G + C) - (600 / N), where N is the length 
of the oligonucleotide (Sam brook et a/, ·t989). Candidate probe sequences 
were then analyzed for homology with TCRBY sequences and other 
sequences that may be present in blood and skin samples by the usc of the 
FastA program (Genetics Computer Group, present in the Molecu lar 
B io logy Package at Leicester University, Vers ion 6.05). Up to 1000 
homologies were checked for each probe. Any probe sequences showing 
sign.i ficant homology with any other BY fiunily or with any other sequence 
of relevance were rejected . A total of25 probes complementary to mRNA 
sequences was tl1en synthesized and purified by high perfomtance liquid 
clu·omatography (Genosys Biotechnologies, Cam bridge, U.K.). For BY5, 
two probes were required to allow detection of aU fami ly members (Table 
Ill). Probe nomenclatu re was rearranged to correspond with the officially 
designated TCRBV gene sequences reporred by Arden et a/ (1995) . The 
gene segments recognized by each probe, and the associated GenBank/ 
EMBL accession numbers used in probe design, arc given in Table ll. Gene 
segment nomenclature is as recently reported (Arden eta/, 1995), where the 
character A refers to alleles and an additional N indicates a difference only 
by nonproductive substimtion. The character 0 is appended ro assign 
orpha n genes and P indicates pseudogcnes. T refers to tentative ly predicted 
alle les that remain to be confirmed as true all eles. 
Dot Blotting Wizard- puri fied second-round PCR products were sepa-
rated into 25 100-ng aliquots, each of which was applied to a Hybond-N 
nylon membrane (Amersham, U .K.) by using a Bio-Rad dot blottiJ1g 
apparatus in accordance wiclt the manufacturer's protocol. Briefly, eDNA 
was denatured by boiLing in 400 mM NaOH/ 10 mM ethylenediamine 
tetraacetic acid for 10 min. Samples were then chilled on ice and adj usted to 
1 M ammonium acetate, and the eDNA aliquots were applied to rhe 
membrane, which was washed with 2X standard saline citrate (0.3 M NaCI, 
0.3 M sodium citrate), air-dried, and baked at 80°C for 2 h. Sets of blots to 
be hybridized with individual probes were pre-hybridized ac 42 °C with 500 
[J.l of hybridization solu tio n [5 X SSPE (0.9 M NaCI, 50 mM sodium 
phosphate, pH 8.3, 5 mM ethylenediamine terraacetic acid), 5 X Denhardt's 
so lution, 0.5% SDS, and 20 J.Lg denatured sa lmon sperm DNA per ml] in a 
2-ml hybridization tube. Each oligonucleotide probe (25 pmol) was labe led 
wi th 10 f.lCi (0 .37 MBq) of dideoxyadenosine 5 ' -[a-3 2 P]triphosphate (185 
TBq/mmol) witl1 terminal deoxynucleotidylc:ransferase. The specific activ-
ity of each probe was calculated by DE-81 /sodium phosphate precipitation 
fo llowed by Cerenkov countiJ1g (Sam brook et a/, 1989). Counts obtained 
were used to normalize the subsequently obta ined hybridization signals with 
respect to the (slightly) different sp ecific activities achieved. T he probes 
were added to the pre-hybridization so lu tion in appropriare rubes and 
hybridization allowed to proceed for 2 h at 42°C. Thereafter dot blots were 
rinsed in SX SSPE/0.5% SDS at room temperature for 15 min and tl1en 
washed at 42°C for 15 min witl1 rwo changes of the same solu tion. Filters 
were then arranged onto damp W batman chromatography paper and sealed 
into plastic befo re being exposed to a Molecular Dynamics ImageQuant 
Phosphorlmager screen for 1-4 d . Images were developed after 24 h tor 
visual inspection ofhybiidization resul ts, but quantit:Ition wirh lmageQuant 
software was carried out on tht' images obtained after a 4-d exposure, co 
increase accuracy. T he amount of each bound probe was expressed as a 
percentage of tl1e sum of all 25 bound probes for each sample. 
CDR3 Size Spcctratyping W here there was an approx.imately 2-fo ld 
increase in percentage expression of a BY family in the biopsy RNA 
compared to autologous PJ3MC !~A and where tl1at BV family also 
represented approximately 5% or more of the total TCR.B V species in the 
biopsy sample, further ana lyses were carried o ut to determine whether the 
apparent expansion was a result of (oligo)clonaJ T-cell accumulation. T his 
was done by TCR B-chain CDR3 size ana lysis (Gorski et al, 1994: 
Yurovsky el a/, 1994) according to a modified protocol provided by Dr. D. 
Holland (Urtiversity of Leeds, U .K.). RNA (25 ng for PBMC or 50 ng for 
biopsy) was converted to eDNA with the CJ3R primer and Superscript II 
reverse transcriptase as described above. eDNA was then amplified in a hot 
PCR using 33P-labelcd C-region primer CJ3! and the relevant Y-region 
primer, as desctibed (Gorski era/, 1994; Yuro vsky el a/, 1 994). The V-region 
prim ers described by Gorski et a/ (1994) were chosen for tlus part of tl1e 
analysis as they had previously been demonstrated to produce satisfactat-y 
CDR3 spcctratypcs. Furthermore, analysis of the published sequences by 
the FastA programme indicated good correlation with the TCRBV gene 
segments listed in Table 11. They had also been tested for positive 
amplifications on eDNA clones represen ting the corresponding BV f.,mi ly 
and tor negative amplification on a mL'<turc of eDNA clones representing 
the other BV fam ilies (Gorski el a/, 1994). To avoid confusion with Y{3 
family nomenclature tue probes named by Gorski el a/ (1994) as 6.1 and 6.2 
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Table II. Designated TCR.BV Gene Segments Recognized by Each Oligonucleotide Probe and Accession Numbers 
Used in Probe Design" 
Designation Designation 
ofTCRBV ofTCRBV 
Probe genes GenBank/EMBL accession number(s) Probe gene GenBank/EMBL accession number(s) 
BVl BV1S1A1N1 M27381 ; M13836; M13 837; M13838; BV8 B V8S 1 X07192; X00437; M14265; U031l5 
M13839; M16834; M27912; X74841 
BV1S1A1N2T M27380 BV8S2A 1T K02546; X07222; X04925; M13858; 
M81773 
BV1S1A2 M27904 BV8S2A2N1T M14264; X57619 
BV2 BV2S1A1 M1 2886; M13842; M13840; M11955; BV8S2A2N2T X57720 
M15222; X57603; 013082; M97719 
BV2S1A2 013087; X72719; M97721 BV8S3 X07223 
BV2S1AJN1 X57604 BV8S4P X07224 
BV2S1AJN2T M14263 BV9 BV9S1A1T Z23044; X57614; X58814; M13859 
BV2S1A4T M11854 BV9S1A2T L06889 
BV2S1A5T X74852 BV9S2A1PT X57608; M33240 
BV2S2A10 L05149 BV10 BV10S1P M13860; M1195 6 
BV2S2A20 X727l7 BV10S20 L05151 
BV2S2AJOT X57605 BV11 BV11S1A1T M13861; M14266 
BV3 BVJS1 X57610; M27382; M13843; X74846; BV11SJA2T X74845 
X04929; X22967; X63456 
BV4 BV4S1AJT Z29590; M13846; M13553 ; X04921; BV11S20P L05152 
M18461; M 197723 
BV4S1A2T X04926 BV12 BV12S1A1N2 U03115 ; Ml4268; X04935 
BV4SJAJT M13847 BV1 2SJA 1N3 M1 3862 
BV4S20 L05150 BV12S2A1T X58808; M64352 
BVSA BV5SJAJT X04927; Ml3849; M1384 8 BV12S2A2T L26230 
BVS1A2T M14271 BV12S2AJT 013084 
BV5S2 X58802 BV12S3 X57609 
BV5SJA1T X57611; M86362 BV13 BV13S1 M13863 ; X04932; Z26594 
BV5SJA2T X57612 BV13S2A1T X61445 
B V5SJA3T X55801 BV13S2A1T L26229; M77498 
BV5S4A1T X58803 BV13S2A2PT M13575; M3134 7 
B V5S4A2T M97709 BV13S3 X61446; X58809 
B V5S5P X61439 BV13S4 X61447 
BV5S6A1T X57615 BV136A1N1T X57721 
BV5S6AJN2T M97707; M73465 ; X68527 BV14 BV14S1 M14267 ; M13865 ; X04928; M17200 
BVSB BV5S2 X58802; M13850 BV15 BV15S1 M11951; M14269 
BV5SJA1T X57611; Ml3551; M14299; X01411; BV15S20P L05153 
M86362 
BV5SJA2T X57612 BV16 BV16S1A1N1 X06154; X04933; X57723; U03115 
BV5SJA3T X55801 BV16S1A1N2 X57722 
BV6 BV6S1A1N1 X04934 BV17 BV17S1A1T M27388 
BVS1AJT M13550; M13852; X04922 BV17S1A2T M97725 
BV6S2A1N1T M11953; M273 83; M13854; M14260 BV17S1A3T L19936 
BV6S2A1N2T M273 84 BV18 BV18S1 M273 89; M1 4270; M15223; M97711 
BVS2A2T X61441 BV19 BV19S1P M27390 
BV6SJA 1N1T X04931; L14480 BV19S20 L26225 
BV6SJAJN2T X58806 BV20 a) M1195 7 
BV6S4A1 X58805; M27386 BV21 BV21S1 M33233 
BV6S4AJT M155 64; Ml3552 BV21S2A1N2T X58797 
BV6S4A4T M14261 BV21S2A2 U03115; X56665; M33234 
BV6S4A5N1T M27385 B V2 1S2AJT M62377 
BV6S5A1N1 M14262; Ml 5221; X61442; M24089 BV21S3AJT M33235 
BV6S5A1N2T M27387 BV21SJA2N1T X58796 
BV6S5A2 X61443 B V21SJA2N2T Z23042 
BV6S6A1T X57607 BV22 B V22S1A 1T M62379 
BV6S6A2T L14483 BV22S1A2N1T X58798; X57727 
BV6S7P X61444 B V22S 1A2N2T M64351 
BV6S9P M97503 BV23 BV23S1A1T M62378 
BV7 BV7S1A1N1T M13 855 B V23S 1A2T U03115 ; X57613; X58799 
BV7S1A1N2T X58813; X57728; X74842 BV24 BV24SJAJT M62376 
BV7S2A 1N1T X57618; M13856 B V24S 1A2T X58800; X57725; M73464 
BV7S2A1N2T X57616 BV24S1AJT U03115 
BV7S2A1NJT L06888 
BV7S2A2T X58812 
BV7S3A1T X58811 
BV7SJA2T X57617 
" Probes recognize gene segments as designated by Arden etnl (1995) except for BV20, whjch was based on an accession number reported by lkuta el nl (1985). TCR.BV gene 
segment nomenclature is as described in A1aten"ctls awl Methods . 
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Table lll. Sequences of Oligonucleotide Probes Used in 
Dot Blot Hybridization 
Probe 
Designation 
13Vl 
BV2 
BV3 
BV4 
BV5A 
BVSB 
13V6 
BV7 
BVS 
13V9 
Probe Sequence" 
TGCAAGTCAGGGAACTGTTGTGCG 
TGTTTCGGGAACTGACGATACCAAAACATA 
CCCAGACCTGGGTCTTGTCG 
CATGTTGCTCACAGTCAGAGTTGAGAATGTTAGGTTT 
TGCTCCCAGGAGACAAAGCAGCACCCA 
GCTCAGAGCTATAGTTAGGGAACTGGTGA 
ASCGATCACTGRGCAGCCCTGb 
GCTGTAGACAAACATGAGCTCCGGTGGC 
CACTTCTTGTCCCATCTCTGTCACC 
CAGAAATTTCTTAGAGTCCTGTTTATACCAATAC 
BV10 GGAACACAATCCATCTTTGCTTTCTGTTCACT 
13V11 
BV12 
13 V'l3 
BV14 
BV15 
13V16 
BV17 
BVlS 
BV19 
BV20 
BV21 
BV22 
BV23 
BV24 
AAAATTCTCCGTCCTTATTCTGTAGACTGTTGA 
GCGGTGGTTCTCAGTCTGGTGAC 
TCCTGGGCACACTGCAGTGTCATGCT 
GAAATTCCTCTTCTCTTTTCGAGAGACTTTGTACC 
ATCAGAGATCTCTCCTTTGTTTATATCTTTGACATC 
TTTTCCCATAACACGTCGATACCAATAAAGATTATCAT 
TTCTGAAAGTCATTTACTATCTGTGAGTAGTAGATCAATCTCA 
CCTTCCTCTGGGAGCTGCCGATACC 
GATTCTGTTGATACCAATAAACAAAAGTATGTCCTTTTTCGG 
AACAGAGCTAACACCAACACCGAGACACCA 
GCACCAAAAAGCCACASBCTGBu 
TGAGATTTCATTATTATAAAAGGAAACCAGAAACTCGACTTTCTG 
GGGATGCTTCCTTTATCGCTCTGCATCTTTTCATAAAACGAAAT 
CCAGTACATGACGTTATGGTTCAAAGTCTGAGAAC 
" Oligor~t~ clcotidc probes arc in the .'iizc r:mge 20-45 nuclcotides; Tm is 63 .5-
G9 .5' C. 
1
' Probe mixtures containing substitutions (R = A+ G: S = G+ C; B = G+T + C) 
were gcner:-~tcd to allow recognitio n of all respective .BV f.1rnily members. 
that recognize different BV6 subgroups are hereafter referred to as 6A and 
6B. After amplifi cation (initial denaturation at 95 ' C for 5 min followed by 
3 7 cycles of 95 ' C for 30 s, 65 ' C for 30 s, and 72 ' C for 60 s and a fmal 
extension at 72 ' C for 5 min) , a portion of each PCR product was separated 
on a 50-cm 5% polyac ryhimide sequencing gel, and radioactive bands were 
analyzed by Phosphor Imager. The region of the gel corresponding to bands 
of 140-200 base pairs in size was selected, band intensities were deter-
mined, and each band was expressed as a percentage of total bands for each 
spectra type. 
RESULTS 
Assay Reproducibility RNA extra cted from the PBMCs of a 
normal donor was sep a.rated into four 50-ng aliquots that were 
reverse-transcribed in sepa.rate parallel experiments and subjected 
to independent anchored PCR reactions and dot blot analysis. A 
high level of reproducibili ty was demonstrated (Fig 1). The 
reproducibility of replicate assays incorporating RNA (four 200-ng 
aliquots) fi-om a lesional skin biopsy of patient F (see below) was 
similar to that obtain ed with PBMC samples (data not shown) . Data 
obtained with RNA from the clin ically n01·mal skin of patient F, 
however, showed replicate variabili ty in excess of three times that 
obtained with RNA from PBMCs or lesional skin biopsy (data not 
shown) . T his is probably due to the veq sm all amount of TCR 
RNA in normal skin samples. For tlus reason we have not 
attempted to decrease the total RNA input below 200 ng for 
lesional skin or 50 ng for PBMC samples. Experiments with 
increasing RNA input (200 , 500, and 1000 ng of lesional skin 
RNA) showed a similar TCRBV profile for these three concentra-
tions (data not shown) . 
For both PCR. stages of the assay, 20 cycles of amplifica tion have 
been selected. Experiments carried out with fewer cycles (ten and 
15 cycles at each stage) yielded less reliable results. With ten cycles 
at each PCR step, all but the most abundant BV funulies were 
undetectable. When TCR B-chain eDN A was subjected to 20, 30, 
and 40 rounds of amplification, progressive skewing toward the 
BV6 and BV14 fa milies was observed with increasing numbers of 
cycles, apparently at the expense of other families including 2, 10, 
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Figure 1. High level of r eproducibility shown on quadruplica te 
analysis of TCRBV usage by PBMCs from a single normal donor. 
T he RNA extract was separated in to fo ur identical aliquots and processed in 
separate parallel assays. 
12, and 13 (data not shown). We th erefore elected to use 20 rounds 
of ampli fi cation at each stage in aU subsequent experim ents. 
T he reproducibility of the anchored PCR a.nd dot blotting assay 
is further demonstrated in Fig 2, wluch shows the results of analysis 
of PBMC and skin biopsy samples from ten patients with psoriasis, 
where each analysis has been carried out in duplicate . 
Skewing of TCRBV Expression in Early Skin Lesions versus 
Autologous PBMC If significant expan sion of a specific BV 
fanuly is defined as an approximately 2-fold greater percentage 
expression in lesiona.l 11erstts PBMC sa.mples, wid1. the relevant 
lesionaJ BV family forming at least 5% of tota.l lesional BV species, 
d1en significa.nt exp an sion was observed in seven of ten patients. 
These expansions involved BV2, BV6, BVS, BVlO, BV12, BV14, 
and BV15, and three of the patients had two significantly expanded 
families (Fig 2, Table IV). With d1e more stringent requirem ent 
that the relevant lesional BV family should form at least 10% of the 
tota l lesional BV species, the number of patients demonstrating 
sign.ifica.nt lesional BV expansion is reduced to five of ten. In this 
case significant expansion was limited to one family per biopsy 
sample: BV2 in two patients, BV6 il1 two patients, and BV14 il1 one 
patient (Fig 2, Table IV). 
TCRBV Profiles of PBMC from Psoriasis Patients and 
Healthy Volunteers Are Similar Duplicated ana.lysis of BV 
expression by PBMC from the four healthy subjects showed 
repertoires that were generally similar to d1ose of the ten ps01iasis 
patients (Fig 3). In both populations BV6 was the most abundant 
fa mily, a findil1g that agrees with the results of Rosenberg et a/ 
(1992) who quantified an chored PCR products by sequence a.nal-
ysis of M1.3 TCR recombinants. 
CDR3 Size Spectratyping Shows Evidence for Clonal T-
Cell Expansion in Some Early Psoriasis Lesions The BV 
fumilies showing an approximately 2-fold greater percentage ex-
pression in lesions JJersus PBMCs and fom1ing at least 5% of tota.l 
lesional BV species (Table IV) were selected for CDR3 specrra-
typillg. Analysis of CDR3 size in patient A, who demonstrated an 
increase in lesional BV14 (Fig 2, Table IV), showed that a.lthough 
60% ofBV1 4 in peripheral blood was of one CDR3 size, in the skin 
there were four size classes of approximately equal in tensi ty and 
one minor class, indicating nonclonal lesional expan sion. In the 
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Table IV. BV Families Showing an Approximately 2-
Fold Expansion in Skin versus PBMCs and Representing 
More Than 5% of the Total Lesional BV Expression" 
same patient, BV2 was expand ed to more than 10% oflesional BV 
but the related CDR3 size was distributed among several species 
and was approximately the same as in PBMCs, again indicating 
nonclonal accumu.lation (Fig 4). T he moderate expansion ofBV15 
in patient l3 (Fig 2, Table IV) was due hngely to a single CDR3 
species representing 45'Yf, of lesional BV15. Tlus BV15 CDR3 size 
distribution suggests moderate clonaJ expansion in the skin, tlus 
species being associated with 28% of p eripheral blood BV15 . T he 
20.----------------------------------, 
a 
Figure 3. Mean TCR BV usage by PBMCs of four normal subjects 
(A) and ten patients with untreated psoriasis (B) is similar. Each 
PBMC extract was assayed in duplicate. Data in (B) were calculated by 
combining the resul ts of the PBMC analyses shown in Fig 2. En·or bars, SD. 
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Patienl F Patient F Patient H Patient H Patient H Patient I 
BV6B BV8 BV6A BV6B BV12 BV14 
PBMC skin PBMC skin PBMC skin PBMC skin PBMC skin PBMC skin 
5.3 1.3 100 100 .!.4 0.4 4.5 1.1 4.3 1.9 .!.8 1.7 
1.!.0 8.0 4 . .! .!.4 7.0 3 . .! 1.2 1.1 5.8 4.7 
.!5.0 4 . .! 8.0 7.3 9.1 5 . .! 1.8 4.7 13.5 15.2 
18. 1 8.1 7 . .! 7.3 8.4 4.3 5.5 2.0 20.9 18.6 
14.7 0.3 78. 1 8.!.5 19.5 11.4 85.4 89. 1 14 . .! .!5.5 
124.7 78.01 51.5 74.7 0.7 0.9 .:!0.9 18.6 
5 . .! 5.3 
11 .7 5.5 
.!.4 3.6 
2.6 !..! 
Figure 4. CDRJ size spectra of TCR chains associated with ex-
panded BV species in lesional ve~•sus PBMC extracts from seven 
psoriasis patients, showing evidence for clonal T-ccll accumula-
tion in some lesional samples. Phosphorlmager-detected radioactive 
bands on polyacrylam..ide sequencing gels are shown for each PBMC and 
skin sample. The colunu1s of numbers associated with each gel show the 
percentage each radioactive band forms of the total bands of the spectra-
type. Spectratype band numbers that arc refeLTed to in the text and signify 
clonal T-ce!J accum ulation are boxed. 
lesional skin of patient D showed moderate expansion ofBV10 (Fig 
2, Table IV) due to a single CDR3 size. Tb!! periphera.l blood of 
dtis patient, however, a.lso yie lded only one BV10 CDR3 size, a 
phenomenon previously reported in nonnal individua.ls (Gorski et 
nl, 1994). Patient E showed lesionaJ BV2 ell:pansion making up 
m ore than 10% of total lesional BV (Fig 2, Table IV). Whereas 
the PBMCs of this patient showed a range of BV2-associated 
CDR.3 sizes, the lesionaJ sample demonstrated one major CDR3 
species making up 41 % oflesional vers1-1s 5% ofPBMCs, indicating 
preferential accumulation of a BV2-expressing T - cell clone in the 
lesion (Fig 4) . In patien t F, w ho demonstrated expanded BV6 
(> 30%) and BV8 (5%) il1 the lesional sample (Fig 2, Table IV), 
BV8 was represented by a single CDR3 size il1 both PBMCs and 
lesion (Fig 4), indicating the in1portance of detennining both 
lesionaJ and peripheraJ blood clona.lity in these circumstances . For 
BV6 CDR3 spectratyping, two primers designated BV6A and 
BV6B were used as il1 the previously described methods (Gorski et 
nl, 1994). W ith primer 6A, a single CDR3 size represented 72% of 
lesional BV6-expressil1g TCR B chains as opposed to 32% in 
peripheral blood in patient F. Similarly, with primer 6B a sil1gle 
CDR 3 size represented 78% of lesional BV6 as opposed to 25% in 
peripheral blood. T lus is lughly suggestive of selective clonal 
accumulation of BV6-expressing T cells in th e lesional sample of 
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this pati en t. Patient H demonstrated increases in mean BV6 (ap-
proximately 20°11>) and BVl2 (5%) in the lesional sample (Fig 2, 
Table IV). The BV12 CDR3 profile was restricted but similar in 
the lesiona l and PBMC samples . T he BV6A CDR3 profile also 
showed similar dominant bands in lesion and blood. There was a 
dominant BV6B CDR3 band in blood (52°;(,) increasing modestly to 
75'!/o in the lesional sample (Fig 4), but this was not strongly 
suggestive of significant clonal expansion ofBV 6-expressing T cells 
in the lesion of this patient. Finally, the increased lesion a) BV14 of 
patient J (Fig 2, Table IV) was associated with a range of CDR3 
sizes without evidence for clonal T -cell expansion (Fig 4). 
DISCUSSION 
T his report describes the application of anchored PCR to the 
analysis of TCR species in small tissue samples, whereas previous 
studies used PBMCs (Rosenberg et al, 1992; Kohsaka eta/, 1993) or 
T -cel l lines (Loh el al, 19S9), both of which are available in 
potentially large amou nts and are likely to contain a higher 
proportion of readily extractable TCR mRNA. The current ana-
lytica l system was established only after a prolonged period of 
development, as poorly reproducible results were obtained without 
rigorous standardization, including the need to purify and quantify 
eDNA at each step. The reproducible resu lts obtained, and the 
likelihood that anchored PCR will generate TCR B-chain species 
that bear a more quantitative relationship to each other than in 
assays incorporating multiple BV -fiunily-specific primers (Genevee 
et a/, 1992; Hall and Finn, 1992; Rosenberg el a/, 1992; Kobsaka et 
a/ , 1993) , highlight the potential value of the present method. 
Anchored PCR involves the use of a nonspecific 5' primer and, 
therefore, introduces the potential to prime multiple trm1cated 
eDNA species that may cause interference with proportional am-
plification. This leads to the need for purification of fint- round 
PCR products by gel electrophoresis, as used in the current work, 
and increases the complexity of the analysis. In attempting to 
minimize bias during PCR, the number of cycles was kept to the 
lowest number compatibLe with the detection of PCR products by 
dot blot hybridization. A reduction below 20 cycles per PCR step 
did not allow · tlus, only the most abundant BV famiHes being 
detectable when, for example , ten cycles were used in each of the 
semi-nested PCR stages. 
CDR.3 size spectratypi:ng conveniently allows more rapid and 
complete determination of the clonality of tissue and blood TCR 
repertoires than conventional cloning and sequencing procedures. 
It should be appreciated, however, that in spectratypes with a 
Gaussian distribution, showing particularly intense bands in the 
middle, central high backgrounds may possibly obscure central 
clona l bands. With these issues in mind, our methods have 
provided evidence for skewing of the TCR repertoire and for 
limited clonal T -cell expansion in early psoriasis vulgaris lesions, 
a.lthough this was not demonstrated in all biopsy samples, and 
unlike previous reports (Lewis et a/, 1. 993; Chang eta/, 1994; Leung 
ef a/, 1. 995; Menssen et al, 1995), there was no consistently increased 
expression of selected BV families . Thus, our results and the 
findings ofMenssen eta/ (1.995) and Lewis et al (1993) in established 
chro•uc plaque psoriasis suggest that selective BV expression is 
more pronounced in es tabLished than early psotiasis vulgaris and 
that specific T -cell responses may be more important in the 
m aintenance or expansion than initiation of lesions . To explore this 
possibility furth er, work is in progress to analyze BV expression in 
established extensive active chronic plaque psoriasis by the an-
chored PCR method and, where possible, to compare early with 
estab lished lesions in the same patient. If more pronounced usage of 
BV2 and BV6 is confmned, the results would hold considerable 
promise for the use of therapeutic TCR peptide vaccination in 
psoriasis, especially in view of the evidence that TCR peptide 
vaccines may induce both humoral and cellular immune responses 
in human subjects (Bourdette et al, 1994; Chou et al, 1.994). As six 
of ten skin biopsy samples, however, did not demonstrate overex-
pression of BV2 or BV6 in the current work, our findings do not 
concur compl etely with the proposal (Menssen et a/, 1995) that T 
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cells expressing these TCR fumi)jes preferen tially home to human 
skin. 
T he above results contrast with the findings of Chang et al (1994) 
who obtained large (3 cm2 ) shave biopsies from psoriasis lesions , 
isolated CD4 + and CDS + T cells, and determined TCRBV usage 
in the purified subpopulations . Substantial increases in expression of 
BV3 or BV13S1 (or both) were found in CDS + cells from 9 of 11 
biopsies. The differences between these findings and those of others 
have been attributed to the use of 0.4-mm-thick epidermal kera-
totome biopsies by Chang et a/ (1994) and full-thickness biopsies 
including dermis by others (Menssen et a/, 1995) . We expect, 
however, that the keratotome biopsies would have contained a 
substantial component of dermal lymphocytes, especially consider-
ing the characteristic irregular hyperplasia and suprapapillary thin-
ning of psoriatic lesional epidermis (Camp, 1992) and the fa ct that 
a major portion of lesional T cell s accumulate immediately below 
the derma-epidermal junction in the papillary dermis (Lewis et a/, 
1993). Thus, the different findings of Chang ef a/ (1994) are more 
)jkely to be attributable to th e analysis of purified T - cell subpopu-
lations and the other analytical methods used, as well as possible 
immunogenetic differences between patient populations. Inte rest-
ingly, whereas increased lesional BV6 usage was previously found 
only in psm;asis patients who were human leukocyte antigen 
HLA-A2-positive (Menssen eta/, 1995), in the present work patient 
H, who overexpressed lesional BV6, was HLA-A11/ A24-positive. 
fn the current work, necessarily small biopsies only a few 
mimmeters in diameter were taken, as the aim was to study early 
lesions . The small size of the samples is unlikely to have allowed 
recovery of sufficient numbers of T cells for purification and 
analysis of separated CD4 + and CDS + subsets, and .it therefore 
remains possible that clonality among CDS + T cells was missed. 
Fmther work is therefore underway to re-explore TCR gene usage 
in purifted subpopulations ofT cells from psoriatic plaques. Clari-
fication of these issues is a mandatory prerequisite to the design of 
TCR-directed immunotherapy for psoriasis patients. 
We are gmttflll to Dr. D . Holla1111, UllitJersity of L eeds, U.K., for arl11ice a/Jo 11l 
CDR3 spectrntypi11_g. This work was SIIJ!JlOrted by J~lel/com e Tmst project awl 
eq11ipment gra11ts (rtference.s 037395/Z / 92/Z and 039375/Z/93 /Z). 
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